Non-peptidic inhibitors of human chymase. Synthesis, structure-activity relationships, and pharmacokinetic profiles of a series of 5-amino-6-oxo-1,6-dihydropyrimidine-containing trifluoromethyl ketones

Citation
F. Akahoshi et al., Non-peptidic inhibitors of human chymase. Synthesis, structure-activity relationships, and pharmacokinetic profiles of a series of 5-amino-6-oxo-1,6-dihydropyrimidine-containing trifluoromethyl ketones, BIO MED CH, 9(2), 2001, pp. 301-315
Citations number
43
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Chemistry & Analysis
Journal title
BIOORGANIC & MEDICINAL CHEMISTRY
ISSN journal
0968-0896 → ACNP
Volume
9
Issue
2
Year of publication
2001
Pages
301 - 315
Database
ISI
SICI code
0968-0896(200102)9:2<301:NIOHCS>2.0.ZU;2-5
Abstract
Chymase possesses a wide variety of actions, including promotion of angiote nsin II production and histamine release from mast cells. However, due to a lack of effective inhibitors featuring both high inhibitory activity and h igh metabolic stability, the pathophysiological role of chymase has not bee n fully elucidated. We designed non-peptidic inhibitors based on the predic ted binding mode of the peptidic chymase inhibitor Val-Pro-Phe-CF3 and demo nstrated that the Val-Pro unit is replaceable with a (5-amino-6-oxo-2-pheny l-1,6-dihydro-1-pyrimidinyl)acetyl moiety. Structure-activity relationship studies revealed that phenyl substitution at the 2-position of the pyrimidi none ring is indispensable for high activity. The most potent compound 1h ( K-i = 0.0506 muM) is superior in potency to the parent peptidic inhibitor V al-Pro-Phe-CF3 and has good selectivity for chymase over other proteases. T he related analogue 1e was orally absorbed and maintained high plasma level s for at least 2 h. These results suggest that the derivatives reported her e could be developed as agents for treatment of chymase-induced disease. (C ) 2001 Elsevier Science Ltd. All rights reserved.